<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35562894</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">4504</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23094504</ELocationID>
        <Abstract>
          <AbstractText>Amyotrophic lateral sclerosis (ALS) is a degenerating disease involving the motor neurons, which causes a progressive loss of movement ability, usually leading to death within 2 to 5 years from the diagnosis. Much effort has been put into research for an effective therapy for its eradication, but still, no cure is available. The only two drugs approved for this pathology, Riluzole and Edaravone, are onlyable to slow down the inevitable disease progression. As assessed in the literature, drug targets such as protein kinases have already been extensively examined as potential drug targets for ALS, with some molecules already in clinical trials. Here, we focus on the involvement of another very important and studied class of biological entities, G protein-coupled receptors (GPCRs), in the onset and progression of ALS. This workaimsto give an overview of what has been already discovered on the topic, providing useful information and insights that can be used by scientists all around the world who are putting efforts into the fight against this very important neurodegenerating disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bassani</LastName>
            <ForeName>Davide</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-9057-6297</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pavan</LastName>
            <ForeName>Matteo</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-6234-5934</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Federico</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-2800-5287</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spalluto</LastName>
            <ForeName>Giampiero</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sturlese</LastName>
            <ForeName>Mattia</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3944-0313</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moro</LastName>
            <ForeName>Stefano</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-7514-3802</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LJ087RS6F</RegistryNumber>
          <NameOfSubstance UI="D019782">Riluzole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S798V6YJRP</RegistryNumber>
          <NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALS</Keyword>
        <Keyword MajorTopicYN="N">GPCR</Keyword>
        <Keyword MajorTopicYN="N">adenosine</Keyword>
        <Keyword MajorTopicYN="N">adrenergic</Keyword>
        <Keyword MajorTopicYN="N">amyotrophic</Keyword>
        <Keyword MajorTopicYN="N">cannabinoid</Keyword>
        <Keyword MajorTopicYN="N">glutamate</Keyword>
        <Keyword MajorTopicYN="N">histamine</Keyword>
        <Keyword MajorTopicYN="N">sclerosis</Keyword>
        <Keyword MajorTopicYN="N">serotonin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35562894</ArticleId>
        <ArticleId IdType="pmc">PMC9106011</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23094504</ArticleId>
        <ArticleId IdType="pii">ijms23094504</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adams J., Lee M., Peng W. Critical Review of Complementary and Alternative Medicine Use in Amyotrophic Lateral Sclerosis: Prevalence and Users’ Profile, Decision-Making, Information Seeking, and Disclosure in the Face of a Lack of Efficacy. Neurodegener. Dis. 2018;18:225–232. doi: 10.1159/000492946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000492946</ArticleId>
            <ArticleId IdType="pubmed">30248676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heckman C., Enoka R.M.  Handbook of Clinical Neurophysiology. Elsevier; Amsterdam, The Netherlands: 2004. Physiology of the motor neuron and the motor unit; pp. 119–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1567-4231(04)04006-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId>
            <ArticleId IdType="pmc">PMC2656493</ArticleId>
            <ArticleId IdType="pubmed">19192301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardiman O., Al-Chalabi A., Chiò A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17071. doi: 10.1016/S0140-6736(10)61156-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId>
            <ArticleId IdType="pubmed">28980624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortí J.D.L.R., Armero J., Sanchis-Sanchis C., Sancho-Castillo S., Salazar A., Caplliure-Llopis J., Navarro-Illana E., Barrios C., Escribá-Alepuz J., Benlloch M. Muscle Function Differences between Patients with Bulbar and Spinal Onset Amyotrophic Lateral Sclerosis. Does It Depend on Peripheral Glucose? J. Clin. Med. 2021;10:1582.  doi: 10.3390/jcm10081582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm10081582</ArticleId>
            <ArticleId IdType="pmc">PMC8069029</ArticleId>
            <ArticleId IdType="pubmed">33918552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098. doi: 10.1016/s0140-6736(17)31287-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(17)31287-4</ArticleId>
            <ArticleId IdType="pubmed">28552366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute of Neurological Disorders and Stroke  Amyotrophic Lateral Sclerosis (ALS) Fact Sheet.  [(accessed on 22 March 2022)]; Available online:  www.ninds.nih.gov.</Citation>
        </Reference>
        <Reference>
          <Citation>Saitoh Y., Takahashi Y. Riluzole for the treatment of amyotrophic lateral sclerosis. Neurodegener. Dis. Manag. 2020;10:343–355. doi: 10.2217/nmt-2020-0033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/nmt-2020-0033</ArticleId>
            <ArticleId IdType="pubmed">32847483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breiner A., Zinman L., Bourque P.R. Edaravone for amyotrophic lateral sclerosis: Barriers to access and lifeboat ethics. Can. Med. Assoc. J. 2020;192:E319–E320. doi: 10.1503/cmaj.191236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1503/cmaj.191236</ArticleId>
            <ArticleId IdType="pmc">PMC7101182</ArticleId>
            <ArticleId IdType="pubmed">32392516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2018;39:733–748. doi: 10.1002/med.21528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/med.21528</ArticleId>
            <ArticleId IdType="pubmed">30101496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918–1929. doi: 10.1111/ene.14393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.14393</ArticleId>
            <ArticleId IdType="pmc">PMC7540334</ArticleId>
            <ArticleId IdType="pubmed">32526057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boddy S.L., Giovannelli I., Sassani M., Cooper-Knock J., Snyder M.P., Segal E., Elinav E., Barker L.A., Shaw P.J., McDermott C.J. The gut microbiome: A key player in the complexity of amyotrophic lateral sclerosis (ALS) BMC Med. 2021;19:13.  doi: 10.1186/s12916-020-01885-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-020-01885-3</ArticleId>
            <ArticleId IdType="pmc">PMC7816375</ArticleId>
            <ArticleId IdType="pubmed">33468103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130–133. doi: 10.1126/science.1134108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1134108</ArticleId>
            <ArticleId IdType="pubmed">17023659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jo M., Lee S., Jeon Y.-M., Kim S., Kwon Y., Kim H.-J. The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies. Exp. Mol. Med. 2020;52:1652–1662. doi: 10.1038/s12276-020-00513-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s12276-020-00513-7</ArticleId>
            <ArticleId IdType="pmc">PMC8080625</ArticleId>
            <ArticleId IdType="pubmed">33051572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suk T., Rousseaux M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId>
            <ArticleId IdType="pmc">PMC7429473</ArticleId>
            <ArticleId IdType="pubmed">32799899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berdyński M., Miszta P., Safranow K., Andersen P.M., Morita M., Filipek S., Żekanowski C., Kuźma-Kozakiewicz M. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci. Rep. 2022;12:103. doi: 10.1038/s41598-021-03891-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-03891-8</ArticleId>
            <ArticleId IdType="pmc">PMC8742055</ArticleId>
            <ArticleId IdType="pubmed">34996976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishigaki S., Sobue G. Importance of Functional Loss of FUS in FTLD/ALS. Front. Mol. Biosci. 2018;5:44. doi: 10.3389/fmolb.2018.00044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmolb.2018.00044</ArticleId>
            <ArticleId IdType="pmc">PMC5943504</ArticleId>
            <ArticleId IdType="pubmed">29774215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eck R.J., Kraemer B.C., Liachko N.F. Regulation of TDP-43 phosphorylation in aging and disease. GeroScience. 2021;43:1605–1614. doi: 10.1007/s11357-021-00383-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11357-021-00383-5</ArticleId>
            <ArticleId IdType="pmc">PMC8492835</ArticleId>
            <ArticleId IdType="pubmed">34032984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo W., Vandoorne T., Steyaert J., Staats K.A., Van Den Bosch L. The multifaceted role of kinases in amyotrophic lateral sclerosis: Genetic, pathological and therapeutic implications. Brain. 2020;143:1651–1673. doi: 10.1093/brain/awaa022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa022</ArticleId>
            <ArticleId IdType="pmc">PMC7296858</ArticleId>
            <ArticleId IdType="pubmed">32206784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palomo V., Nozal V., Rojas-Prats E., Gil C., Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. J. Cereb. Blood Flow Metab. 2020;178:1316–1335. doi: 10.1111/bph.15221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.15221</ArticleId>
            <ArticleId IdType="pubmed">32737989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;65:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moro S., Bissaro M. Rethinking to riluzole mechanism of action: The molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. Neural Regen. Res. 2019;14:2083–2085. doi: 10.4103/1673-5374.262578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1673-5374.262578</ArticleId>
            <ArticleId IdType="pmc">PMC6788255</ArticleId>
            <ArticleId IdType="pubmed">31397342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcia P., Beltran S., Bakkouche S., Couratier P. Therapeutic news in ALS. Rev. Neurol. 2021;177:544–549. doi: 10.1016/j.neurol.2020.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2020.12.003</ArticleId>
            <ArticleId IdType="pubmed">33781562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Springer Nature  AdisInsight—Small-Molecules in Clinical Trials for ALS.  [(accessed on 31 March 2022)].  Available online:  https://adisinsight.springer.com/search.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen H., Kankel M.W., Su S.C., Han S.W.S., Ofengeim D. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. Cell Death Differ. 2018;25:648–662. doi: 10.1038/s41418-018-0060-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0060-4</ArticleId>
            <ArticleId IdType="pmc">PMC5864209</ArticleId>
            <ArticleId IdType="pubmed">29459769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Insel P.A., Wilderman A., Zambon A.C., Snead A.N., Murray F., Aroonsakool N., McDonald D.S., Zhou S., McCann T., Zhang L., et al.  G Protein–Coupled Receptor (GPCR) Expression in Native Cells: “Novel” endoGPCRs as Physiologic Regulators and Therapeutic Targets. Mol. Pharmacol. 2015;88:181–187. doi: 10.1124/mol.115.098129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.115.098129</ArticleId>
            <ArticleId IdType="pmc">PMC4468643</ArticleId>
            <ArticleId IdType="pubmed">25737495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gacasan S.B., Baker D.L., Parrill A.L. G protein-coupled receptors: The evolution of structural insight. AIMS Biophys. 2017;4:491–527. doi: 10.3934/biophy.2017.3.491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3934/biophy.2017.3.491</ArticleId>
            <ArticleId IdType="pmc">PMC6018013</ArticleId>
            <ArticleId IdType="pubmed">29951585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y., Basith S., Choi S. Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. J. Med. Chem. 2017;61:1–46. doi: 10.1021/acs.jmedchem.6b01453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b01453</ArticleId>
            <ArticleId IdType="pubmed">28657745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heng B.C., Aubel D., Fussenegger M. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol. Adv. 2013;31:1676–1694. doi: 10.1016/j.biotechadv.2013.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biotechadv.2013.08.017</ArticleId>
            <ArticleId IdType="pubmed">23999358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes C., Kaster M., Tome A., Agostinho P., Cunha R.A. Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochim. Biophys. Acta. 2011;1808:1380–1399. doi: 10.1016/j.bbamem.2010.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2010.12.001</ArticleId>
            <ArticleId IdType="pubmed">21145878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincenzi F., Corciulo C., Targa M., Casetta I., Gentile M., Granieri E., Borea P.A., Popoli P., Varani K. A2Aadenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2013;14:406–413. doi: 10.3109/21678421.2013.793358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/21678421.2013.793358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida Y., Une F., Utatsu Y., Nomoto M., Furukawa Y., Maruyama Y., Machigashira N., Matsuzaki T., Osame M. Adenosine and Neopterin Levels in Cerebrospinal Fluid of Patients with Neurological Disorders. Intern. Med. 1999;38:133–139. doi: 10.2169/internalmedicine.38.133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.38.133</ArticleId>
            <ArticleId IdType="pubmed">10225668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potenza R.L., Armida M., Ferrante A., Pèzzola A., Matteucci A., Puopolo M., Popoli P. Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2013;91:585–592. doi: 10.1002/jnr.23185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.23185</ArticleId>
            <ArticleId IdType="pubmed">23361938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori A., Cross B., Uchida S., Walker J.K., Ristuccia R. How Are Adenosine and Adenosine A2A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis? Biomedicines. 2021;9:1027.  doi: 10.3390/biomedicines9081027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biomedicines9081027</ArticleId>
            <ArticleId IdType="pmc">PMC8392384</ArticleId>
            <ArticleId IdType="pubmed">34440231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng S.K., Higashimori H., Tolman M., Yang Y. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2015;267:115–122. doi: 10.1016/j.expneurol.2015.03.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2015.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC5363273</ArticleId>
            <ArticleId IdType="pubmed">25779930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mojsilovic-Petrovic J., Jeong G.-B., Crocker A., Arneja A., David S., Russell D., Kalb R.G. Protecting Motor Neurons from Toxic Insult by Antagonism of Adenosine A2a and Trk Receptors. J. Neurosci. 2006;26:9250–9263. doi: 10.1523/JNEUROSCI.1856-06.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1856-06.2006</ArticleId>
            <ArticleId IdType="pmc">PMC6674510</ArticleId>
            <ArticleId IdType="pubmed">16957081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y.-J., Ju T., Chen H.-M., Jang Y.-S., Lee L.-M., Lai H.-L., Tai H.-C., Fang J.-M., Lin Y.-L., Tu P.-H., et al.  Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014;24:787–801. doi: 10.1093/hmg/ddu497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddu497</ArticleId>
            <ArticleId IdType="pubmed">25256353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morillas A.G., Besson V., Lerouet D. Microglia and Neuroinflammation: What Place for P2RY12? Int. J. Mol. Sci. 2021;22:1636.  doi: 10.3390/ijms22041636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22041636</ArticleId>
            <ArticleId IdType="pmc">PMC7915979</ArticleId>
            <ArticleId IdType="pubmed">33561958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amadio S., Parisi C., Montilli C., Carrubba A.S., Apolloni S., Volonté C. P2Y12 Receptor on the Verge of a Neuroinflammatory Breakdown. Mediat. Inflamm. 2014;2014:975849. doi: 10.1155/2014/975849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/975849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobson K.A., Delicado E.G., Gachet C., Kennedy C., Von Kügelgen I., Li B., Miras-Portugal M.T., Novak I., Schöneberg T., Perez-Sen R., et al.  Update of P2Y receptor pharmacology: IUPHAR Review 27. J. Cereb. Blood Flow Metab. 2020;177:2413–2433. doi: 10.1111/bph.15005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.15005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Ambrosi N., Finocchi P., Apolloni S., Cozzolino M., Ferri A., Padovano V., Pietrini G., Carrì M.T., Volonté C. The Proinflammatory Action of Microglial P2 Receptors Is Enhanced in SOD1 Models for Amyotrophic Lateral Sclerosis. J. Immunol. 2009;183:4648–4656. doi: 10.4049/jimmunol.0901212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901212</ArticleId>
            <ArticleId IdType="pubmed">19734218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi K., Yamanaka H., Fukuoka T., Dai Y., Obata K., Noguchi K. P2Y12 Receptor Upregulation in Activated Microglia Is a Gateway of p38 Signaling and Neuropathic Pain. J. Neurosci. 2008;28:2892–2902. doi: 10.1523/JNEUROSCI.5589-07.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5589-07.2008</ArticleId>
            <ArticleId IdType="pmc">PMC6670682</ArticleId>
            <ArticleId IdType="pubmed">18337420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore C.S., Ase A.R., Kinsara A., Rao V.T., Michell-Robinson M., Leong S.Y., Butovsky O., Ludwin S.K., Séguéla P., Bar-Or A., et al.  P2Y12 expression and function in alternatively activated human microglia. Neurol. Neuroimmunol. Neuroinflamm. 2015;2:e80. doi: 10.1212/NXI.0000000000000080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000080</ArticleId>
            <ArticleId IdType="pmc">PMC4370387</ArticleId>
            <ArticleId IdType="pubmed">25821842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Cognata V., Golini E., Iemmolo R., Balletta S., Morello G., De Rosa C., Villari A., Marinelli S., Vacca V., Bonaventura G., et al.  CXCR2 increases in ALS cortical neurons and its inhibition prevents motor neuron degeneration in vitro and improves neuromuscular function in SOD1G93A mice. Neurobiol. Dis. 2021;160:105538. doi: 10.1016/j.nbd.2021.105538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2021.105538</ArticleId>
            <ArticleId IdType="pubmed">34743985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinovich-Nikitin I., Ezra A., Barbiro B., Rabinovich-Toidman P., Solomon B. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS. J. Neuroinflamm. 2016;13:123. doi: 10.1186/s12974-016-0587-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0587-6</ArticleId>
            <ArticleId IdType="pmc">PMC4882847</ArticleId>
            <ArticleId IdType="pubmed">27230771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu E., Karpf L., Bohl D. Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions with Neurons. Front. Mol. Neurosci. 2021;14:767041. doi: 10.3389/fnmol.2021.767041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2021.767041</ArticleId>
            <ArticleId IdType="pmc">PMC8712677</ArticleId>
            <ArticleId IdType="pubmed">34970118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perner C., Perner F., Stubendorff B., Förster M., Witte O.W., Heidel F.H., Prell T., Grosskreutz J. Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. J. Neuroinflamm. 2018;15:99. doi: 10.1186/s12974-018-1135-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-018-1135-3</ArticleId>
            <ArticleId IdType="pmc">PMC5874995</ArticleId>
            <ArticleId IdType="pubmed">29592817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawajiri M., Mogi M., Higaki N., Tateishi T., Ohyagi Y., Horiuchi M., Miki T., Kira J.-I. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009;119:341–344. doi: 10.1111/j.1600-0404.2008.01099.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2008.01099.x</ArticleId>
            <ArticleId IdType="pubmed">18798831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwasaki Y., Ichikawa Y., Igarashi O., Kinoshita M., Ikeda K. Trophic effect of Olmesartan, a novel AT1R antagonist, on spinal motor neuronsin vitroandin vivo. Neurol. Res. 2002;24:468–472. doi: 10.1179/016164102101200357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/016164102101200357</ArticleId>
            <ArticleId IdType="pubmed">12117316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mammana S., Fagone P., Cavalli E., Basile M.S., Petralia M.C., Nicoletti F., Bramanti P., Mazzon E. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. Int. J. Mol. Sci. 2018;19:831.  doi: 10.3390/ijms19030831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19030831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borasio G.D., Linke R., Schwarz J., Schlamp V., Abel A., Mozley P.D., Tatsch K. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography. J. Neurol. Neurosurg. Psychiatry. 1998;65:263–265. doi: 10.1136/jnnp.65.2.263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.65.2.263</ArticleId>
            <ArticleId IdType="pmc">PMC2170216</ArticleId>
            <ArticleId IdType="pubmed">9703186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai C.-Y., Liu Y.-J., Lai H.-L., Chen H.-M., Kuo H.-C., Liao Y.-P., Chern Y. The D2 Dopamine Receptor Interferes With the Protective Effect of the A2A Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration. Front. Neurosci. 2018;12:187. doi: 10.3389/fnins.2018.00187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00187</ArticleId>
            <ArticleId IdType="pmc">PMC5869924</ArticleId>
            <ArticleId IdType="pubmed">29615863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X., Roet K.C., Zhang L., Brault A., Berg A.P., Jefferson A.B., Klug-McLeod J., Leach K.L., Vincent F., Yang H., et al.  Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validation. Cell Rep. 2021;35:109224. doi: 10.1016/j.celrep.2021.109224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.109224</ArticleId>
            <ArticleId IdType="pmc">PMC8209673</ArticleId>
            <ArticleId IdType="pubmed">34107252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al.  Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579–1589. doi: 10.1038/s41591-018-0140-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId>
            <ArticleId IdType="pubmed">30127392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dooley M., Markham A. Pramipexole. Drugs Aging. 1998;12:495–514. doi: 10.2165/00002512-199812060-00007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00002512-199812060-00007</ArticleId>
            <ArticleId IdType="pubmed">9638397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gribkoff V.K., Bozik M.E. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrochloride monohydrate] for the Treatment of Amyotrophic Lateral Sclerosis. CNS Neurosci. Ther. 2008;14:215–226. doi: 10.1111/j.1755-5949.2008.00048.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1755-5949.2008.00048.x</ArticleId>
            <ArticleId IdType="pmc">PMC6494033</ArticleId>
            <ArticleId IdType="pubmed">18801114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kingwell K. Dexpramipexole shows promise for ALS in phase II trial. Nat. Rev. Neurol. 2011;8:4. doi: 10.1038/nrneurol.2011.204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2011.204</ArticleId>
            <ArticleId IdType="pubmed">22198402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cudkowicz M.E., Berg L.H.V.D., Shefner J.M., Mitsumoto H., Mora J.S., Ludolph A., Hardiman O., Bozik M.E., Ingersoll E.W., Archibald D., et al.  Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId>
            <ArticleId IdType="pubmed">24067398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Oussini H., Bayer H., Scekic-Zahirovic J., Vercruysse P., Sinniger J., Dirrig-Grosch S., Dieterlé S., Echaniz-Laguna A., Larmet Y., Müller K., et al.  Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathol. 2016;131:465–480. doi: 10.1007/s00401-016-1534-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-016-1534-4</ArticleId>
            <ArticleId IdType="pubmed">26744351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dentel C., Palamiuc L., Henriques A., Lannes B., Spreux-Varoquaux O., Gutknecht L., René F., Echaniz-Laguna A., De Aguilar J.-L.G., Lesch K.P., et al.  Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: A link to spasticity. Brain. 2013;136:483–493. doi: 10.1093/brain/aws274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws274</ArticleId>
            <ArticleId IdType="pubmed">23114367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnoux A., Ayme-Dietrich E., Dieterle S., Goy M.-A., Schann S., Frauli M., Monassier L., Dupuis L. Evaluation of a 5-HT2B receptor agonist in a murine model of amyotrophic lateral sclerosis. Sci. Rep. 2021;11:23582. doi: 10.1038/s41598-021-02900-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-02900-0</ArticleId>
            <ArticleId IdType="pmc">PMC8654833</ArticleId>
            <ArticleId IdType="pubmed">34880312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elangbam C.S., Job L.E., Zadrozny L.M., Barton J.C., Yoon L.W., Gates L.D., Slocum N. 5-Hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp. Toxicol. Pathol. 2008;60:253–262. doi: 10.1016/j.etp.2008.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.etp.2008.03.005</ArticleId>
            <ArticleId IdType="pubmed">18511249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacomblez L., Bensimon G., Douillet P., Doppler V., Salachas F., Meininger V. Xaliproden in amyotrophic lateral sclerosis: Early clinical trials. Amyotroph. Lateral Scler. 2004;5:99–106. doi: 10.1080/14660820410018973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14660820410018973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lecca D., Raffaele S., Abbracchio M.P., Fumagalli M. Regulation and signaling of the GPR17 receptor in oligodendroglial cells. Glia. 2020;68:1957–1967. doi: 10.1002/glia.23807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.23807</ArticleId>
            <ArticleId IdType="pubmed">32086854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., Zhao C., Zhang X., Huang X., Shi W., Fang S., Lu Y., Zhang W., Xia Q., Wei E. The new P2Y-like receptor G protein-coupled receptor 17 mediates acute neuronal injury and late microgliosis after focal cerebral ischemia in rats. Neuroscience. 2011;202:42–57. doi: 10.1016/j.neuroscience.2011.11.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2011.11.066</ArticleId>
            <ArticleId IdType="pubmed">22155652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonfanti E., Bonifacino T., Raffaele S., Milanese M., Morgante E., Bonanno G., Abbracchio M.P., Fumagalli M. Abnormal Upregulation of GPR17 Receptor Contributes to Oligodendrocyte Dysfunction in SOD1 G93A Mice. Int. J. Mol. Sci. 2020;21:2395.  doi: 10.3390/ijms21072395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21072395</ArticleId>
            <ArticleId IdType="pmc">PMC7177925</ArticleId>
            <ArticleId IdType="pubmed">32244295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merten N., Fischer J., Simon K., Zhang L., Schröder R., Peters L., Letombe A.-G., Hennen S., Schrage R., Bödefeld T., et al.  Repurposing HAMI3379 to Block GPR17 and Promote Rodent and Human Oligodendrocyte Differentiation. Cell Chem. Biol. 2018;25:775–786.e5. doi: 10.1016/j.chembiol.2018.03.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chembiol.2018.03.012</ArticleId>
            <ArticleId IdType="pmc">PMC6685917</ArticleId>
            <ArticleId IdType="pubmed">29706593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raffaele S., Boccazzi M., Fumagalli M. Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives. Cells. 2021;10:565.  doi: 10.3390/cells10030565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10030565</ArticleId>
            <ArticleId IdType="pmc">PMC8000560</ArticleId>
            <ArticleId IdType="pubmed">33807572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin S., Wang X., Xiang X., Wu Y., Hu J., Li Y., Dong Y.L., Tan Y., Wu X. Inhibition of GPR17 with cangrelor improves cognitive impairment and synaptic deficits induced by Aβ1–42 through Nrf2/HO-1 and NF-κB signaling pathway in mice. Int. Immunopharmacol. 2021;101:108335. doi: 10.1016/j.intimp.2021.108335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2021.108335</ArticleId>
            <ArticleId IdType="pubmed">34781121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marschallinger J., Schäffner I., Klein B., Gelfert R., Rivera F.J., Illes S., Grassner L., Janssen M., Rotheneichner P., Schmuckermair C., et al.  Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat. Commun. 2015;6:8466. doi: 10.1038/ncomms9466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9466</ArticleId>
            <ArticleId IdType="pmc">PMC4639806</ArticleId>
            <ArticleId IdType="pubmed">26506265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burnstock G. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology. 2016;104:4–17. doi: 10.1016/j.neuropharm.2015.05.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2015.05.031</ArticleId>
            <ArticleId IdType="pubmed">26056033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartus R.T., Bétourné A., Basile A., Peterson B.L., Glass J., Boulis N.M. β 2 -Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS) Neurobiol. Dis. 2016;85:11–24. doi: 10.1016/j.nbd.2015.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2015.10.006</ArticleId>
            <ArticleId IdType="pubmed">26459114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng Y.D., Choi H., Huang W., Onario R.C., Frontera W.R., Snyder E.Y., Sabharwal S. Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis. Neurosci. Lett. 2006;397:155–158. doi: 10.1016/j.neulet.2005.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2005.12.007</ArticleId>
            <ArticleId IdType="pubmed">16388902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apolloni S., Fabbrizio P., Amadio S., Napoli G., Verdile V., Morello G., Iemmolo R., Aronica E., Cavallaro S., Volonté C. Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Front. Immunol. 2017;8:1689. doi: 10.3389/fimmu.2017.01689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01689</ArticleId>
            <ArticleId IdType="pmc">PMC5714870</ArticleId>
            <ArticleId IdType="pubmed">29250069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volonté C., Apolloni S., Sabatelli M. Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS) Pharmacol. Ther. 2019;202:120–131. doi: 10.1016/j.pharmthera.2019.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2019.06.006</ArticleId>
            <ArticleId IdType="pubmed">31233766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W., Zhang X., Zhang Y., Qu C., Zhou X., Zhang S. Histamine Induces Microglia Activation and the Release of Proinflammatory Mediators in Rat Brain Via H1R or H4R. J. Neuroimmune Pharmacol. 2019;15:280–291. doi: 10.1007/s11481-019-09887-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11481-019-09887-6</ArticleId>
            <ArticleId IdType="pubmed">31863333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apolloni S., Fabbrizio P., Parisi C., Amadio S., Volonté C. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2014;53:518–531. doi: 10.1007/s12035-014-9019-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-014-9019-8</ArticleId>
            <ArticleId IdType="pubmed">25482048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzon E., Giacoppo S. Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regen. Res. 2016;11:1896–1899. doi: 10.4103/1673-5374.197125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1673-5374.197125</ArticleId>
            <ArticleId IdType="pmc">PMC5270417</ArticleId>
            <ArticleId IdType="pubmed">28197175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbi B., Owusu M.A., Hughes I., Katz M., Broadley S., Sabet A. Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: A systematic review and meta-analysis. J. Neurochem. 2018;149:284–297. doi: 10.1111/jnc.14639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.14639</ArticleId>
            <ArticleId IdType="pubmed">30520038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoemaker J.L., Seely K.A., Reed R.L., Crow J.P., Prather P.L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 2006;101:87–98. doi: 10.1111/j.1471-4159.2006.04346.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2006.04346.x</ArticleId>
            <ArticleId IdType="pmc">PMC2819701</ArticleId>
            <ArticleId IdType="pubmed">17241118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim K., Moore D.H., Makriyannis A., Abood M.E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 2006;542:100–105. doi: 10.1016/j.ejphar.2006.05.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2006.05.025</ArticleId>
            <ArticleId IdType="pubmed">16781706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iłżecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 2003;108:125–129. doi: 10.1034/j.1600-0404.2003.00102.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-0404.2003.00102.x</ArticleId>
            <ArticleId IdType="pubmed">12859290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosuge Y., Nango H., Kasai H., Yanagi T., Mawatari T., Nishiyama K., Miyagishi H., Ishige K., Ito Y. Generation of Cellular Reactive Oxygen Species by Activation of the EP2 Receptor Contributes to Prostaglandin E2-Induced Cytotoxicity in Motor Neuron-Like NSC-34 Cells. Oxidative Med. Cell. Longev. 2020;2020:1–14. doi: 10.1155/2020/6101838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/6101838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bilak M., Wu L., Wang Q., Haughey N., Conant K., St. Hillaire C., Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2004;56:240–248. doi: 10.1002/ana.20179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20179</ArticleId>
            <ArticleId IdType="pubmed">15293276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staines D.R. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides? Med. Hypotheses. 2008;70:413–418. doi: 10.1016/j.mehy.2007.04.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mehy.2007.04.038</ArticleId>
            <ArticleId IdType="pubmed">17582695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwasaki Y., Ikeda K., Ichikawa Y., Igarashi O. Vasoactive intestinal peptide influences neurite outgrowth in cultured rat spinal cord neurons. Neurol. Res. 2001;23:851–854. doi: 10.1179/016164101101199298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/016164101101199298</ArticleId>
            <ArticleId IdType="pubmed">11760877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solés-Tarrés I., Cabezas-Llobet N., Vaudry D., Xifró X. Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide against Cognitive Decline in Neurodegenerative Diseases. Front. Cell. Neurosci. 2020;14:221. doi: 10.3389/fncel.2020.00221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2020.00221</ArticleId>
            <ArticleId IdType="pmc">PMC7380167</ArticleId>
            <ArticleId IdType="pubmed">32765225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waschek J. VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair. J. Cereb. Blood Flow Metab. 2013;169:512–523. doi: 10.1111/bph.12181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.12181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martínez C., Juarranz Y., Gutiérrez-Cañas I., Carrión M., Pérez-García S., Villanueva-Romero R., Castro D., Lamana A., Mellado M., González-Álvaro I., et al.  A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases. Int. J. Mol. Sci. 2019;21:65.  doi: 10.3390/ijms21010065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21010065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anneser J.M.H., Chahli C., Ince P.G., Borasio G.D., Shaw P. Glial Proliferation and Metabotropic Glutamate Receptor Expression in Amyotrophic Lateral Sclerosis. J. Neuropathol. Exp. Neurol. 2004;63:831–840. doi: 10.1093/jnen/63.8.831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnen/63.8.831</ArticleId>
            <ArticleId IdType="pubmed">15330338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milanese M., Giribaldi F., Melone M., Bonifacino T., Musante I., Carminati E., Rossi P.I., Vergani L., Voci A., Conti F., et al.  Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2014;64:48–59. doi: 10.1016/j.nbd.2013.11.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2013.11.006</ArticleId>
            <ArticleId IdType="pubmed">24361555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi D., Brambilla L., Valori C.F., Roncoroni C., Crugnola A., Yokota T., Bredesen D.E., Volterra A. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 2008;15:1691–1700. doi: 10.1038/cdd.2008.99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2008.99</ArticleId>
            <ArticleId IdType="pubmed">18617894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anneser J., Chahli C., Borasio G. Protective effect of metabotropic glutamate receptor inhibition on amyotrophic lateral sclerosis–cerebrospinal fluid toxicity in vitro. Neuroscience. 2006;141:1879–1886. doi: 10.1016/j.neuroscience.2006.05.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2006.05.044</ArticleId>
            <ArticleId IdType="pubmed">16820266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crupi R., Impellizzeri D., Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front. Mol. Neurosci. 2019;12:20. doi: 10.3389/fnmol.2019.00020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2019.00020</ArticleId>
            <ArticleId IdType="pmc">PMC6375857</ArticleId>
            <ArticleId IdType="pubmed">30800054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarrinmayeh H., Territo P.R. Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications. Mol. Imaging. 2020;19:1536012120927609. doi: 10.1177/1536012120927609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1536012120927609</ArticleId>
            <ArticleId IdType="pmc">PMC7297484</ArticleId>
            <ArticleId IdType="pubmed">32539522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borea P.A., Gessi S., Merighi S., Vincenzi F., Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol. Rev. 2018;98:1591–1625. doi: 10.1152/physrev.00049.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00049.2017</ArticleId>
            <ArticleId IdType="pubmed">29848236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–242. doi: 10.1093/nar/28.1.235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/28.1.235</ArticleId>
            <ArticleId IdType="pmc">PMC102472</ArticleId>
            <ArticleId IdType="pubmed">10592235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segala E., Guo D., Cheng R.K.Y., Bortolato A., Deflorian F., Doré A.S., Errey J.C., Heitman L.H., Ijzerman A.P., Marshall F.H., et al.  Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength. J. Med. Chem. 2016;59:6470–6479. doi: 10.1021/acs.jmedchem.6b00653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b00653</ArticleId>
            <ArticleId IdType="pubmed">27312113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chemical Computing Group ULC  . Molecular Operating Environment (MOE) Chemical Computing Group ULC; Montreal, QC, Canada: 2021. </Citation>
        </Reference>
        <Reference>
          <Citation>Burnstock G. Purinergic Signalling: Therapeutic Developments. Front. Pharmacol. 2017;8:661. doi: 10.3389/fphar.2017.00661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2017.00661</ArticleId>
            <ArticleId IdType="pmc">PMC5622197</ArticleId>
            <ArticleId IdType="pubmed">28993732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang K., Zhang J., Gao Z.-G., Zhang D., Zhu L., Han G.W., Moss S.M., Paoletta S., Kiselev E., Lu W., et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014;509:115–118. doi: 10.1038/nature13083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13083</ArticleId>
            <ArticleId IdType="pmc">PMC4174307</ArticleId>
            <ArticleId IdType="pubmed">24670650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes C.E., Nibbs R.J.B. A guide to chemokines and their receptors. FEBS J. 2018;285:2944–2971. doi: 10.1111/febs.14466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.14466</ArticleId>
            <ArticleId IdType="pmc">PMC6120486</ArticleId>
            <ArticleId IdType="pubmed">29637711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agle K.A., Vongsa R.A., Dwinell M.B. Calcium Mobilization Triggered by the Chemokine CXCL12 Regulates Migration in Wounded Intestinal Epithelial Monolayers. J. Biol. Chem. 2010;285:16066–16075. doi: 10.1074/jbc.M109.061416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.061416</ArticleId>
            <ArticleId IdType="pmc">PMC2871475</ArticleId>
            <ArticleId IdType="pubmed">20348095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K., Wu L., Yuan S., Wu M., Xu Y., Sun Q., Li S., Zhao S., Hua T., Liu Z.-J. Structural basis of CXC chemokine receptor 2 activation and signalling. Nature. 2020;585:135–140. doi: 10.1038/s41586-020-2492-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2492-5</ArticleId>
            <ArticleId IdType="pubmed">32610344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Žídek A., Potapenko A., et al.  Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId>
            <ArticleId IdType="pmc">PMC8371605</ArticleId>
            <ArticleId IdType="pubmed">34265844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu B., Chien E.Y.T., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R., Brooun A., Wells P., Bi F.C., et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. Science. 2010;330:1066–1071. doi: 10.1126/science.1194396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1194396</ArticleId>
            <ArticleId IdType="pmc">PMC3074590</ArticleId>
            <ArticleId IdType="pubmed">20929726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh K.D., Karnik S.S. Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. J. Cell Signal. 2016;1:111. doi: 10.4172/jcs.1000111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/jcs.1000111</ArticleId>
            <ArticleId IdType="pmc">PMC4976824</ArticleId>
            <ArticleId IdType="pubmed">27512731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ames M.K., Atkins C.E., Pitt B. The renin-angiotensin-aldosterone system and its suppression. J. Veter. Intern. Med. 2018;33:363–382. doi: 10.1111/jvim.15454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jvim.15454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miura S.-I., Karnik S.S., Saku K. Review: Angiotensin II type 1 receptor blockers: Class effects versus molecular effects. J. Renin-Angiotensin-Aldosterone Syst. 2010;12:1–7. doi: 10.1177/1470320310370852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1470320310370852</ArticleId>
            <ArticleId IdType="pmc">PMC3891529</ArticleId>
            <ArticleId IdType="pubmed">20603272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akishita M., Ito M., Lehtonen J.Y., Daviet L., Dzau V.J., Horiuchi M. Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J. Clin. Investig. 1999;103:63–71. doi: 10.1172/JCI5182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI5182</ArticleId>
            <ArticleId IdType="pmc">PMC407869</ArticleId>
            <ArticleId IdType="pubmed">9884335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H., Unal H., Desnoyer R., Han G.W., Patel N., Katritch V., Karnik S.S., Cherezov V., Stevens R.C. Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor. J. Biol. Chem. 2015;290:29127–29139. doi: 10.1074/jbc.M115.689000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M115.689000</ArticleId>
            <ArticleId IdType="pmc">PMC4705918</ArticleId>
            <ArticleId IdType="pubmed">26420482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perryman R. Inhibition of the angiotensin II type 2 receptor AT2R is a novel therapeutic strategy for glioblastoma. 2022.  
Unpublished Work
.</Citation>
        </Reference>
        <Reference>
          <Citation>Beaulieu J.-M., Gainetdinov R.R. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacol. Rev. 2011;63:182–217. doi: 10.1124/pr.110.002642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.110.002642</ArticleId>
            <ArticleId IdType="pubmed">21303898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallone D., Picetti R., Borrelli E. Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 2000;24:125–132. doi: 10.1016/S0149-7634(99)00063-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0149-7634(99)00063-9</ArticleId>
            <ArticleId IdType="pubmed">10654668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang Y., Xu P., Mao C., Wang L., Krumm B., Zhou X.E., Huang S., Liu H., Cheng X., Huang X.-P., et al.  Structural insights into the human D1 and D2 dopamine receptor signaling complexes. Cell. 2021;184:931–942.e18. doi: 10.1016/j.cell.2021.01.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2021.01.027</ArticleId>
            <ArticleId IdType="pmc">PMC8215686</ArticleId>
            <ArticleId IdType="pubmed">33571431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu P., Huang S., Mao C., Krumm B.E., Zhou X.E., Tan Y., Huang X.-P., Liu Y., Shen D.-D., Jiang Y., et al.  Structures of the human dopamine D3 receptor-Gi complexes. Mol. Cell. 2021;81:1147–1159.e4. doi: 10.1016/j.molcel.2021.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2021.01.003</ArticleId>
            <ArticleId IdType="pubmed">33548201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S., Wacker D., Levit A., Che T., Betz R.M., McCorvy J.D., Venkatakrishnan A.J., Huang X.-P., Dror R.O., Shoichet B.K., et al.  D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science. 2017;358:381–386. doi: 10.1126/science.aan5468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aan5468</ArticleId>
            <ArticleId IdType="pmc">PMC5856174</ArticleId>
            <ArticleId IdType="pubmed">29051383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nichols D.E., Nichols C.D. Serotonin Receptors. Chem. Rev. 2008;108:1614–1641. doi: 10.1021/cr078224o.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cr078224o</ArticleId>
            <ArticleId IdType="pubmed">18476671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frazer A., Hensler J.G.  Serotonin receptors. In: Siegel G.J., Agranoff B.W., Albers R.W., editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Lippincott-Raven; Philadelphia, PA, USA: 1999. </Citation>
        </Reference>
        <Reference>
          <Citation>Xu P., Huang S., Zhang H., Mao C., Zhou X.E., Cheng X., Simon I.A., Shen D.-D., Yen H.-Y., Robinson C.V., et al.  Structural insights into the lipid and ligand regulation of serotonin receptors. Nature. 2021;592:469–473. doi: 10.1038/s41586-021-03376-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03376-8</ArticleId>
            <ArticleId IdType="pubmed">33762731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCorvy J.D., Wacker D., Wang S., Agegnehu B., Liu J., Lansu K., Tribo A.R., Olsen R.H.J., Che T., Jin J., et al.  Structural determinants of 5-HT2B receptor activation and biased agonism. Nat. Struct. Mol. Biol. 2018;25:787–796. doi: 10.1038/s41594-018-0116-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41594-018-0116-7</ArticleId>
            <ArticleId IdType="pmc">PMC6237183</ArticleId>
            <ArticleId IdType="pubmed">30127358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Y., McCorvy J.D., Harpsøe K., Lansu K., Yuan S., Popov P., Qu L., Pu M., Che T., Nikolajsen L.F., et al.  5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell. 2018;172:719–730.e14. doi: 10.1016/j.cell.2018.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC6309861</ArticleId>
            <ArticleId IdType="pubmed">29398112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marucci G., Ben D.D., Lambertucci C., Navia A.M., Spinaci A., Volpini R., Buccioni M. GPR17 receptor modulators and their therapeutic implications: Review of recent patents. Expert Opin. Ther. Patents. 2019;29:85–95. doi: 10.1080/13543776.2019.1568990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13543776.2019.1568990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dziedzic A., Miller E., Saluk-Bijak J., Bijak M. The GPR17 Receptor—A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis. Int. J. Mol. Sci. 2020;21:1852.  doi: 10.3390/ijms21051852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21051852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marucci G., Ben D.D., Lambertucci C., Santinelli C., Spinaci A., Thomas A., Volpini R., Buccioni M. The G Protein-Coupled Receptor GPR17: Overview and Update. ChemMedChem. 2016;11:2567–2574. doi: 10.1002/cmdc.201600453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cmdc.201600453</ArticleId>
            <ArticleId IdType="pubmed">27863043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Insel P.A. Adrenergic Receptors—Evolving Concepts and Clinical Implications. N. Engl. J. Med. 1996;334:580–585. doi: 10.1056/NEJM199602293340907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199602293340907</ArticleId>
            <ArticleId IdType="pubmed">8569827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subbarao K.V., Hertz L. Effect of adrenergic agonists on glycogenolysis in primary cultures of astrocytes. Brain Res. 1990;536:220–226. doi: 10.1016/0006-8993(90)90028-A.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(90)90028-A</ArticleId>
            <ArticleId IdType="pubmed">2085749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel M., Shaw D. A review of standard pharmacological therapy for adult asthma—Steps 1 to 5. Chronic Respir. Dis. 2015;12:165–176. doi: 10.1177/1479972315573529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1479972315573529</ArticleId>
            <ArticleId IdType="pubmed">25711467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F., Ling S., Zhou Y., Zhang Y., Lv P., Liu S., Fang W., Sun W., A Hu L., Zhang L., et al.  Different conformational responses of the β2-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline. Natl. Sci. Rev. 2020;8 doi: 10.1093/nsr/nwaa284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nsr/nwaa284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons M.E., Ganellin C.R. Histamine and its receptors. Br. J. Pharmacol. 2006;147((Suppl. 1)):S127–S135. doi: 10.1038/sj.bjp.0706440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0706440</ArticleId>
            <ArticleId IdType="pmc">PMC1760721</ArticleId>
            <ArticleId IdType="pubmed">16402096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiligada E., Ennis M. Histamine pharmacology: From Sir Henry Dale to the 21st century. J. Cereb. Blood Flow Metab. 2018;177:469–489. doi: 10.1111/bph.14524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.14524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia R., Wang N., Xu Z., Lu Y., Song J., Zhang A., Guo C., He Y. Cryo-EM structure of the human histamine H1 receptor/Gq complex. Nat. Commun. 2021;12:1–9. doi: 10.1038/s41467-021-22427-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-22427-2</ArticleId>
            <ArticleId IdType="pmc">PMC7782487</ArticleId>
            <ArticleId IdType="pubmed">33397941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeepMind  The AlphaFold Database.  [(accessed on 22 March 2022)].  Available online:  https://alphafold.ebi.ac.uk/</Citation>
        </Reference>
        <Reference>
          <Citation>Zou S., Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci. 2018;19:833.  doi: 10.3390/ijms19030833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19030833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaminski N.E. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem. Pharmacol. 1996;52:1133–1140. doi: 10.1016/0006-2952(96)00480-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-2952(96)00480-7</ArticleId>
            <ArticleId IdType="pubmed">8937419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bilsland L.G., Dick J.R.T., Pryce G., Petrosino S., Di Marzo V., Baker D., Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. FASEB J. 2006;20:1003–1005. doi: 10.1096/fj.05-4743fje.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.05-4743fje</ArticleId>
            <ArticleId IdType="pubmed">16571781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hua T., Li X., Wu L., Iliopoulos-Tsoutsouvas C., Wang Y., Wu M., Shen L., Brust C.A., Nikas S.P., Song F., et al.  Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures. Cell. 2020;180:655–665.e18. doi: 10.1016/j.cell.2020.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.01.008</ArticleId>
            <ArticleId IdType="pmc">PMC7898353</ArticleId>
            <ArticleId IdType="pubmed">32004463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing C., Zhuang Y., Xu T.-H., Feng Z., Zhou X.E., Chen M., Wang L., Meng X., Xue Y., Wang J., et al.  Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex. Cell. 2020;180:645–654.e13. doi: 10.1016/j.cell.2020.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC8247115</ArticleId>
            <ArticleId IdType="pubmed">32004460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reader J., Holt D., Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev. 2011;30:449–463. doi: 10.1007/s10555-011-9303-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-011-9303-2</ArticleId>
            <ArticleId IdType="pmc">PMC3640271</ArticleId>
            <ArticleId IdType="pubmed">22002714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson T., Narumiya S., Zeilhofer H.U. Contribution of peripheral versus central EP1 prostaglandin receptors to inflammatory pain. Neurosci. Lett. 2011;495:98–101. doi: 10.1016/j.neulet.2011.03.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2011.03.046</ArticleId>
            <ArticleId IdType="pubmed">21440042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedyk E.R., Phipps R.P. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc. Natl. Acad. Sci. USA. 1996;93:10978–10983. doi: 10.1073/pnas.93.20.10978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.20.10978</ArticleId>
            <ArticleId IdType="pmc">PMC38269</ArticleId>
            <ArticleId IdType="pubmed">8855294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe K., Kawamori T., Nakatsugi S., Ohta T., Ohuchida S., Yamamoto H., Maruyama T., Kondo K., Ushikubi F., Narumiya S., et al.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999;59:5093–5096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10537280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Li Q. Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review) Int. J. Mol. Med. 2018;42:1203–1214. doi: 10.3892/ijmm.2018.3744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2018.3744</ArticleId>
            <ArticleId IdType="pubmed">29956743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi K., Kato S., Amagase K. Prostaglandin EP Receptors Involved in Modulating Gastrointestinal Mucosal Integrity. J. Pharmacol. Sci. 2010;114:248–261. doi: 10.1254/jphs.10R06CR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1254/jphs.10R06CR</ArticleId>
            <ArticleId IdType="pubmed">21041985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang T., Du Y. Distinct Roles of Central and Peripheral Prostaglandin E2 and EP Subtypes in Blood Pressure Regulation. Am. J. Hypertens. 2012;25:1042–1049. doi: 10.1038/ajh.2012.67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajh.2012.67</ArticleId>
            <ArticleId IdType="pmc">PMC3578476</ArticleId>
            <ArticleId IdType="pubmed">22695507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman E.A., Ogletree M.L., Haddad E.V., Boutaud O. Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease. Thromb. Res. 2015;136:493–503. doi: 10.1016/j.thromres.2015.05.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2015.05.027</ArticleId>
            <ArticleId IdType="pmc">PMC4553088</ArticleId>
            <ArticleId IdType="pubmed">26077962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takasaki I., Nojima H., Shiraki K., Sugimoto Y., Ichikawa A., Ushikubi F., Narumiya S., Kuraishi Y. Involvement of cyclooxygenase-2 and EP3 prostaglandin receptor in acute herpetic but not postherpetic pain in mice. Neuropharmacology. 2005;49:283–292. doi: 10.1016/j.neuropharm.2004.12.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2004.12.025</ArticleId>
            <ArticleId IdType="pubmed">15925391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S., Zhou W., Ge J., Zhang Z. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP-PKA/PI3K-Akt signaling pathway. Mol. Med. Rep. 2018;17:4702–4712. doi: 10.3892/mmr.2018.8415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2018.8415</ArticleId>
            <ArticleId IdType="pubmed">29328471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu C., Mao C., Xiao P., Shen Q., Zhong Y.-N., Yang F., Shen D.-D., Tao X., Zhang H., Yan X., et al.  Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E2 receptor EP2 subtype. Sci. Adv. 2021;7:eabf1268. doi: 10.1126/sciadv.abf1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.abf1268</ArticleId>
            <ArticleId IdType="pubmed">33811074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morimoto K., Suno R., Hotta Y., Yamashita K., Hirata K., Yamamoto M., Narumiya S., Iwata S., Kobayashi T. Crystal structure of the endogenous agonist-bound prostanoid receptor EP3. Nat. Chem. Biol. 2018;15:8–10. doi: 10.1038/s41589-018-0171-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41589-018-0171-8</ArticleId>
            <ArticleId IdType="pubmed">30510192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nojima S., Fujita Y., Kimura K.T., Nomura N., Suno R., Morimoto K., Yamamoto M., Noda T., Iwata S., Shigematsu H., et al.  Cryo-EM Structure of the Prostaglandin E Receptor EP4 Coupled to G Protein. Structure. 2020;29:252–260.e6. doi: 10.1016/j.str.2020.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.str.2020.11.007</ArticleId>
            <ArticleId IdType="pubmed">33264604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umetsu Y., Tenno T., Goda N., Shirakawa M., Ikegami T., Hiroaki H. Structural difference of vasoactive intestinal peptide in two distinct membrane-mimicking environments. Biochim. Biophys. Acta (BBA) Proteins Proteom. 2011;1814:724–730. doi: 10.1016/j.bbapap.2011.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbapap.2011.03.009</ArticleId>
            <ArticleId IdType="pubmed">21439408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harmar A.J., Fahrenkrug J., Gozes I., Laburthe M., May V., Pisegna J.R., Vaudry D., Vaudry H., A Waschek J., I Said S. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1. J. Cereb. Blood Flow Metab. 2012;166:4–17. doi: 10.1111/j.1476-5381.2012.01871.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2012.01871.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couvineau A., Laburthe M. VPAC receptors: Structure, molecular pharmacology and interaction with accessory proteins. J. Cereb. Blood Flow Metab. 2012;166:42–50. doi: 10.1111/j.1476-5381.2011.01676.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2011.01676.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan J., Shen D.-D., Zhou X.E., Bi P., Liu Q.-F., Tan Y.-X., Zhuang Y.-W., Zhang H.-B., Xu P.-Y., Huang S.-J., et al.  Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. Nat. Commun. 2020;11:1–10. doi: 10.1038/s41467-020-17933-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-17933-8</ArticleId>
            <ArticleId IdType="pmc">PMC6946686</ArticleId>
            <ArticleId IdType="pubmed">31911652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niswender C.M., Conn P.J. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease. Annu. Rev. Pharmacol. Toxicol. 2010;50:295–322. doi: 10.1146/annurev.pharmtox.011008.145533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pharmtox.011008.145533</ArticleId>
            <ArticleId IdType="pmc">PMC2904507</ArticleId>
            <ArticleId IdType="pubmed">20055706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Qu L., Wu L., Tang X., Luo F., Xu W., Xu Y., Liu Z.-J., Hua T. Structural insights into the activation initiation of full-length mGlu1. Protein Cell. 2020;12:662–667. doi: 10.1007/s13238-020-00808-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-020-00808-5</ArticleId>
            <ArticleId IdType="pmc">PMC8310541</ArticleId>
            <ArticleId IdType="pubmed">33278019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seven A.B., Barros-Álvarez X., de Lapeyrière M., Papasergi-Scott M.M., Robertson M.J., Zhang C., Nwokonko R.M., Gao Y., Meyerowitz J.G., Rocher J.-P., et al.  G-protein activation by a metabotropic glutamate receptor. Nature. 2021;595:450–454. doi: 10.1038/s41586-021-03680-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03680-3</ArticleId>
            <ArticleId IdType="pmc">PMC8822903</ArticleId>
            <ArticleId IdType="pubmed">34194039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin S., Han S., Cai X., Tan Q., Zhou K., Wang D., Wang X., Du J., Yi C., Chu X., et al.  Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4. Nature. 2021;594:583–588. doi: 10.1038/s41586-021-03495-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03495-2</ArticleId>
            <ArticleId IdType="pubmed">34135510</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
